Tavneos' Troubled History: A Warning for Japan's Healthcare System Japan's pharmaceutical industry has been at the forefront of medical innovation, but recent events surrounding Tavneos have raised serious questions about the country's healthcare system.
The warning issued by Kissei Pharmaceutical against prescribing this rare diseases treatment to new patients is a stark reminder that safety and efficacy should never be compromised.
Approved in both the US and Europe for treating autoimmune diseases, Tavneos has been linked to 20 reported deaths since its launch in Japan in June 2022.